Latest Breaking News On - Meeting presentation - Page 1 : comparemela.com

OHCA Publishes Final Regulations For California s New Health Care Transaction Oversight Law - Healthcare

On December 18, 2023, the Office of Administrative Law ("OAL") approved the California Office of Healthcare Affordability's ("OHCA's") Cost and Market Impact Review regulations.

United statesSheila tatayonOffice of administrative lawRopes grayKnox keene health care serviceDepartment of managed health careHealth care market oversightOregon health authorityOregon health authority care market oversightHealth care entityCalifornia office of healthcareCalifornia department of managed health careHealth care entitiesHealth safAdministrative lawCalifornia office

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Northern irelandUnited kingdomUnited statesCastillay leópElcin barker ergunMaria victoria mateosEuropean hematology associationKaryopharm therapeutics incEuropean commissionStemline therapeutics incMenarini groupUniversity hospital salamancaWorld health organizationStemline therapeuticsProfessor maria victoria mateosMeeting presentation

Menarini Industrie Farmaceutiche Riunite: Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Data demonstrate a significant 71% reduction in risk of disease progression or death in selinexor + bortezomib + dexamethasone (SVd) arm versus bortezomib + dexamethasone (Vd) arm in PI-naïve

United statesUnited kingdomNorthern irelandCastillay leópMecklenburg vorpommernElcin barker ergunMaria victoria mateosStefan klotterMenarini groupStemline therapeutics incKaryopharm therapeutics incEuropean hematology associationEuropean commissionWorld health organizationUniversity hospital salamancaStemline therapeutics

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCastillay leópNorthern irelandUnited kingdomMaria victoria mateosElcin barker ergunEuropean hematology associationKaryopharm therapeutics incMenarini groupWorld health organizationStemline therapeutics incEuropean commissionUniversity hospital salamancaStemline therapeuticsVictoria mateosBarker ergun

Menarini Industrie Farmaceutiche Riunite: Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

United statesElcin barker ergunGewinn nurMenarini groupAmerican society of clinical oncologyRadius health incUt health san antonioStemline therapeutics incUs food drug administrationMd anderson cancer centerEuropean medicines agencyStemline therapeuticsAmerican societyClinical oncologyAnnual meetingDrug administration